University of California
Davis, California, 95616, United States
NCT Number: NCT06395324
The FEEDMe Study is a single-group, open label pilot study exploring how diverse, commercially available foods rich in arabinose influence the gut microbiome in adults from diverse populations.
Looking for future studies?
Notify Me18 year–50 year
All sexes
Interventional
Not applicable
Davis, California, 95616, United States
Upon enrollment, healthy adults will enter a 15-day lead-in period during which they will refrain from consuming specific foods and collect a baseline stool sample. The intervention period will be on days 16-33 during which participants will consume study provided high-arabinose foods. The follow-up period will be on days 34-49 during which participants will no longer eat the study foods and will refrain from consuming specific foods. The total duration of the study will be approximately 7 weeks. Stool samples will be collected on 3 occasions and participants will be asked to complete questionnaires, daily stool logs, dietary intake reports, and 24-hour dietary recalls throughout the course of the study.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Participants will consume a high arabinose diet for 18 consecutive days.
Time frame: Change from baseline to days 31 and 47
Examine changes to the concentration and distribution of fecal microbiota in response to consuming a high arabinose diet as measured by 16s rRNA sequencing and metagenomics.
Time frame: Change from baseline to days 31 and 47
Determine changes in fecal glycome in response to consumption of a high arabinose diet as measured by metagenomic analysis and mass spectrometry.
Time frame: Change from baseline to days 31 and 47
Determine changes in fecal SCFAs in response to consumption of a high arabinose diet as measured by mass spectrometry.
Time frame: Change from baseline to days 31 and 47
Assess gastrointestinal tolerance to a high arabinose diet as measured by questionnaires that ask participants to report gastrointestinal symptoms. A list of GI symptoms are listed in the weekly survey and participants will select none, mild, moderate, severe or unsure. The proportion of severe responses will be compared across the study weeks.
Time frame: Change from baseline to days 16-33
Determine changes in fecal consistency and frequency in response to a high arabinose diet as measured by questionnaires that ask participants to report their number of stools per day and to rank the consistency of their stools using the Bristol Stool Scale. For seven days prior to each of the three stool collections, participants will rate their stool consistency on a scale from 1-7 and these values will be averaged and compared across the three time points (pre, during and post high arabinose diet). This scale is not continuous but rather nominal and the proportion of 4 and 5 is considered "normal" stoo consistency.
Time frame: Intervention period: days 31-46
Examine overall acceptability and sensory perceptions of high arabinose commercially available products as measured by questionnaires. Participants will rate how much they like each study food after consuming each one for the first time on a continuous scale from 0 to 100 where 0 equals did not like at all and 100 equals extremely liked. The scores will be reported for each food.
Time frame: Study period: Days 1-49
Evaluate the overall satisfaction of participants' experience for feedback on the study protocol and study duration. At the end of the study, participants will rate their satisfaction on a continuous scale from 0 to 100, where 0 equals not satisfied at all and 100 equals extremely satisfied.
Time frame: Follow-up period: days 34-49
Evaluate if 14 days of avoiding arabinose foods is a sufficient washout period to result in changes in concentration and distribution of gut microbiota as measured by 16s rRNA sequencing and metagenomics.
Time frame: Change from baseline to days 31 and 47
Determine changes in fecal immune and inflammatory markers such as levels of immunoglobulins in response to a high arabinose diet as measured by ELISA and mass spectrometry.
Time frame: Change from baseline to days 31 and 47
Determine changes in fecal metabolites and organic acids in response to a high arabinose diet as measured by mass spectrometry.
Time frame: Study period: Days 1-49
Determine the feasibility of executing the study design in two different populations: 1) medium and high income and 2) low-income communities at-risk for gut dysbiosis by comparing attrition rates among the two groups.
Time frame: Study period: Days 1-49
Determine the feasibility in adults consuming a high arabinose diet over 2.5 week period by assessing adherence to the study protocol and attrition rates.
Time frame: Study period: Days 1-49
Determine differences for all primary and secondary endpoints between middle/high income and low-income participants in response to a high arabinose diet by stratifying data based on these two groups.
Time frame: Study period: Days 1-49
Determine if the study resulted in any Adverse Events and Serious Adverse Events by administering a questionnaire that asks participants to report the occurrence of any illness and health care visits for sickness. Participants complete weekly questionnaires and report if they experienced any illnesses or hospital visits. The proportion of these incidence will be reported across the three time points (pre, during and post high arabinose diet).
University of California, Davis
Other
Acronym: FEEDMe
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05765422
Communicable Diseases, Disease Attributes
Nice, France
View Trial DetailsNCT07092046
Anesthesia Circuit, Anesthesia Equipment Bacterial Contamination
Ankara, Turkey (Türkiye)
View Trial DetailsNCT07045636
Communicable Diseases, Digestive System Diseases
Guarulhos, São Paulo, Brazil
View Trial DetailsNCT05065671
Communicable Diseases, Disease Attributes
Somerville, New Jersey, United States
View Trial Details